Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus

Abstract

ObjectivesThis study aimed to evaluate the specificity, sensitivity, cost, and turn-around time of three methods of gene polymorphism analysis and to study the relationship between IL28B rs12979860 and SVR rate to pegIFN-α/RVB therapy among patients with chronic hepatitis C.MethodsA total of 100 samples from chronic hepatitis C patients were analyzed in parallel using the three methods: direct sequencing, real-time polymerase chain reaction (PCR), amplification refractory mutation system (ARMS)-PCR.ResultsThe different profiles for IL28B rs12979860 alleles (CC, CT, and TT) obtained with PCR-RFLP, ARMS-PCR, and direct sequencing were consistent among the three methods. Prevalence of rs12979860 genotypes CC, CT and TT in HCV genotype 1a was 10(19.6%), 35(68.6%), and six (11.8%), respectively, and in HCV genotype 31, it was 13(26.5%), 31(63.3%), and five (10.2%), respectively. No significant difference was seen between rs12979860 genotype and HCV genotype (p = 0.710).ConclusionScreening by ARMS – PCR SNOP detection represents the most efficient and reliable method to determine HCV polymorphisms in routine clinical practice.

Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection

“…Frequencies of CT genotype in NR group and relapsers were 72.7% and 100%, respectively. This finding is consistent with those of previous studies (16,28,30).…”

“…These studies have reported that this assay is simple, fast, inexpensive, and valid. This method is applicable in every molecular diagnostic laboratory with PCR-RFLP assay capability (16).…”

“…This method can be used by every molecular diagnostic laboratory with PCR-RFLP assay capability. Determining this polymorphism will be clinically useful in predicting treatment response in participants with HCV infection (15,16).…”

Polymorphic Variants of the Gene of Interferon Lambda 3 and Features of Immune Response in Children With Chronic Viral Hepatitis C

“…Курс лечения при 1-м генотипе вируса гепатита С состав-лял 48 нед, при 2-м и 3-м генотипах -24 недели. Всем детям с хроническим вирусным гепатитом С до старта терапии и на ее фоне (4,8,12,16, 24 и 48-я недели лечения) проводились антропометрические, биохимические, молекулярно-генетические и дру-гие параклинические исследования. Контрольную группу составили 25 здоровых детей того же возраста русской национальности, обследование которых про-водилось при диспансерном наблюдении в условиях поликлиники.…”

“…Новые возможно-сти в лечении хронического вирусного гепатита С появились в связи с открытием ассоциативной связи полиморфизма локуса ДНК гена IL28B, который по сути является представителем интерферона-лямбда 3 (IFN-λ3) и ответом на лечение интерфероном-α в комбинации с рибавирином [2,3]. Многочисленны-ми исследованиями, проведенными у взрослых, по-казано, что пациенты с 1-м генотипом вируса гепа-тита С, гомозиготные по С-аллелю rs 12979860 гена IFN-λ3, имеют больше шансов достичь устойчивого вирусологического ответа в сравнении с пациентами, имеющими Т-аллель [4].…”